This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): ranolazine; Latixa
Description: While its exact mechanism of action is unknown, Ranexa appears to be a selective inhibitor of the late sodium current. This is thought to prevent sodium overload and resulting calcium overload in the heart, which occur during both ischemia and heart failure but not in the normal heart. (Due to preclinical studies with high concentrations of Ranexa, it was initially thought to work by inhibiting fatty acid oxidation and increasing glucose oxidation, but subsequent studies showing inhibition of the late sodium current at concentrations consistent with the dosages used in clinical trials have indicated that this is the more likely mechanism of action.)
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
In March 1996, CV entered into a license agreement with Syntex (now Roche) to obtain United States and foreign patent rights to Ranexa for the treatment of angina and other cardiovascular indications. Syntex provided initial quantities of the compound for use in clinical trials and related development activities. The license agreement is exclusive and worldwide except for the following countries which Syntex has licensed exclusively to Kissei Pharmaceuticals, Ltd. of Japan: Japan, Korea, China, Taiwan, Hong Kong, the Philippines, Indonesia, Singapore, Thailand, Malaysia, Vietnam, Myanmar, Laos, Cambodia and Brunei.
Under the license agreement, CV paid an initial license fee, and are obligated to make certain milestone payments to Syntex, upon receipt of the first and second product approvals for Ranexa in any of certain major market countries (consisting of France, Germany, Italy, the United States and...See full deal structure in Biomedtracker
Partners: Roche Holding AG The Menarini Group
Additional information available to subscribers only: